“World’s First” Gene Therapy Drugs Against Aging Are Being Developed in Russia
Scientists are creating a drug to block the RAGE gene (cell aging) and a therapy for sarcopenia based on exosomes from young cells, which has shown rejuvenation of old cells.
“World’s First” Gene Therapy Drugs Against Aging: A Russian Breakthrough
Introduction
In April 2026, at an all-Russian conference in Saransk organized under the “For Healthy Longevity Medicine” movement, Deputy Minister of Science and Higher Education of the Russian Federation Denis Sekirinsky made an announcement that drew the attention of the global scientific community. Russian scientists announced the start of development of two world-first gene therapy drugs aimed at combating cellular aging processes.
These initiatives mark a paradigm shift in gerontology: instead of fighting individual age-associated diseases, researchers intend to target the fundamental mechanisms of aging. The first drug is aimed at blocking the RAGE gene—a receptor whose activation triggers a cascade of cellular aging. The second targets sarcopenia (progressive loss of muscle mass and strength) using exosomes—extracellular vesicles that cells use for intercellular communication.
Particularly noteworthy is that both projects are being implemented under the national project “New Technologies for Health Preservation,” launched on the instructions of President Vladimir Putin. The program’s budget exceeds 2 trillion rubles (about $26.4 billion), underscoring the status of the research as a state-level priority.
Event Details and Timeline
Announcement at the Saransk Conference
On April 23–24, 2026, an all-Russian off-site conference on the development of healthy longevity medicine was held in Saransk. The event was attended by politicians, public figures, leading experts in healthcare and medical science, as well as over 300 doctors from across the country. It was at this venue that Denis Sekirinsky publicly presented the ambitious plans of Russian science.
Quoting the Deputy Minister: “The RAGE gene is a receptor whose activation triggers cell aging; blocking this gene, on the contrary, can prolong its youth. This principle has formulated an ambitious task—to develop the world’s first gene therapy drug that purposefully blocks the aforementioned receptor.”
Drug #1: Blocking the RAGE Gene
RAGE (Receptor for Advanced Glycation End Products) is a protein located on the surface of cells. Its activation occurs under the influence of various stress factors—chronic inflammation, oxidative stress, and advanced glycation end products that accumulate with age. The triggered cascade of signaling pathways leads to increased apoptosis (programmed cell death), accumulation of pro-inflammatory cytokines, and acceleration of aging processes.
The idea of blocking RAGE is not new in global science—various studies in animal models have demonstrated a slowdown of age-related changes when this receptor is suppressed. However, according to Russian officials, the proposal to create a gene therapy drug for humans based on this principle is the first in the world. The development is being carried out by the Institute of Aging Biology and Healthy Longevity Medicine in Moscow.
Drug #2: Exosome Therapy for Sarcopenia
The second direction is related to age-related muscle loss—sarcopenia. This condition, affecting up to 30% of people over 60 and more than 50% over 80, significantly reduces quality of life, increases the risk of falls, fractures, and loss of independence. The key problem, emphasized by Sekirinsky: “Once it develops, it is no longer possible to restore physical abilities through exercise.”
Researchers from the Petrovsky Russian Scientific Center of Surgery obtained experimental data back in 2025 that formed the basis for this development. Preclinical studies demonstrated:
| Type of Transfer | Result |
|---|---|
| Exosomes from aging cells → young cells | Multiple enhancement of inflammation, accelerated aging |
| Exosomes from young cells → aging cells | Rejuvenation of cells |
These results open an exciting prospect: exosomes produced by young cells contain “youth signals”—microRNAs, proteins, and lipids capable of reprogramming the metabolism of old cells toward a younger phenotype. A platform for producing such drugs already exists—the first exosome product in Russia was developed by Lomonosov Moscow State University for the treatment of male infertility.
Timeline of Preceding Events
It is important to note that the 2026 announcement did not come out of nowhere. As early as 2025, Deputy Prime Minister Tatyana Golikova stated at the forum “Russia and the World: Trends in Healthy Longevity” that Russian scientists plan to develop drugs that restore aging cells, as well as biomedical cell products for treating brain and spinal cord injuries, wounds, and burns, in 2028–2030. She called these developments a priority of the new national project.
Planned Timelines and Target Groups
According to information released during the conference, the use of the new drugs should begin in 2030. They are planned to be prescribed to:
- People with signs of premature aging
- Patients at high risk of cardiovascular pathologies and dementia
The government is currently discussing the possibility of including these high-tech and expensive methods in compulsory health insurance programs or providing benefits to certain categories of citizens under the active longevity strategy.
Impact and Significance
For Global Medical Science
If the announced developments are successfully completed and pass clinical trials, Russia could take a leading position in the field of gerontology and gene therapy for aging. To date, there are no registered drugs in the world that purposefully target the fundamental mechanisms of human aging. Most existing approaches—from metformin to senolytics (drugs that destroy aging cells)—are at various stages of clinical trials, but none have achieved registration as a “drug for aging.”
The parallel development of two different approaches (RAGE blockade and exosome therapy) creates potential synergy. The scale of funding (over 2 trillion rubles for the entire national project) is comparable to the largest international initiatives in this area, such as the US Advanced Research Projects Agency for Health (ARPA-H) or European projects under the Healthy Longevity Initiative.
For Gerontology and Practical Medicine in Russia
For Russia, facing demographic challenges (according to official statistics, the average life expectancy for men is about 67 years), the development of means to extend active longevity has strategic importance. Success in this area could lead to:
- Reducing the burden on the pension and healthcare systems—longer preservation of working capacity in the elderly
- Decreasing the prevalence of age-associated diseases—cardiovascular pathologies, neurodegenerative disorders, sarcopenia
- Improving the quality of life for millions of elderly citizens
Director of the Petrovsky Russian Scientific Center of Surgery Konstantin Kotenko previously emphasized: “A promising direction in aging biology is the development of biomedical products containing exosomes. These are extracellular vesicles with biological markers.”
For Society
The announcement of the creation of “vaccines against old age” has generated widespread public resonance. On one hand, it raises hopes for the possibility of radically extending active life. On the other, it raises complex ethical questions: who will get access to these technologies first? Will they exacerbate social inequality if they remain accessible only to the wealthy?
It is important to note the conceptual difference between the two approaches. Blocking the RAGE gene involves a one-time gene therapy intervention (similar to existing drugs for treating hereditary diseases), while exosome therapy will likely require course administration. The government is already discussing the possibility of including these methods in compulsory health insurance programs, which could mitigate the accessibility issue.
Reactions of Key Players
Official Position of Russian Authorities
The announcement was made at a high state level—by the Deputy Minister of Science and Higher Education. Previous statements by Deputy Prime Minister Tatyana Golikova and the existence of a presidential directive indicate that the projects are under the direct patronage of the country’s leadership. Denis Sekirinsky emphasized that the research relies on “advanced genetic technologies and represents one of the most promising paths in the fight against aging.”
Scientific Community and Expert Assessments
According to Western sources, the project’s curator and the source of the “obsessive idea of eternal life” is said to be Mikhail Kovalchuk, a long-time associate of President Putin and head of the Kurchatov Institute. Kovalchuk also oversees the federal genetics development program, in which, according to some reports, the president’s alleged eldest daughter, endocrinologist Maria Vorontsova, participates.
In the Russian scientific community, based on publications, the initiatives are viewed with cautious optimism. On one hand, the experimental data obtained in 2025 (rejuvenation of old cells by exosomes from young cells) is indeed a scientific fact requiring further study. On the other hand, the path from convincing cellular experiments to a registered drug for humans is extremely long and fraught with obstacles. Animal studies are needed, followed by phases of clinical trials (I–III), which could take 7–12 years even under optimal circumstances.
International Context
Russia’s claim of “world-first” drugs should be considered in the context of the global race for leadership in longevity technologies. The US is investing billions in ARPA-H, European countries are developing networks of healthy longevity centers, and private companies (Altos Labs, Calico, Retro Biosciences) are attracting tens of billions of dollars from major investors.
The Russian initiative stands out for its state nature and direct presidential patronage. Unlike private initiatives aimed at profit, the Russian project is formally focused on solving demographic problems and improving the quality of life of the population, which could simplify obtaining regulatory approvals within the country.
Forecast and Conclusions
Realistic Assessment of Prospects
- Blocking the RAGE gene: Creating a gene therapy drug to suppress RAGE expression is a task comparable in complexity to developing existing gene therapies (e.g., Zolgensma for spinal muscular atrophy). Such drugs exist for monogenic diseases, but for aging—a process involving thousands of genes—the “one gene, one drug” strategy may be an oversimplification. The safety of long-term RAGE blockade in humans is unknown (the receptor also performs beneficial functions, e.g., in immune response).
- Exosome therapy: This approach appears more technologically feasible within the next 5–7 years. Protocols for exosome isolation and purification already exist, and clinical studies of exosome therapy for various diseases are underway. However, the key issue is standardization: exosomes obtained from different donors or batches may have variable composition and activity. Scaling production to industrial volumes is another serious engineering challenge.
Development Scenarios
Optimistic scenario (probability ~20%): By 2030, preclinical and early clinical trials (phases I–II) are successfully completed. The drugs demonstrate acceptable safety and convincing signs of efficacy (slowing age-related decline in muscle strength, improving aging biomarkers). Limited use begins under “early access programs” for patients with premature aging or severe sarcopenia.
Realistic scenario (probability ~50%): By 2030, preclinical studies are completed, and phases I–II of clinical trials begin. Initial safety and efficacy data are published. Registration of the drugs and the start of widespread clinical use are postponed to 2032–2035.
Pessimistic scenario (probability ~30%): Unforeseen safety issues arise (e.g., RAGE blockade leads to increased susceptibility to infections or malignant neoplasms), or exosome therapy does not show a reproducible effect in humans sufficient for clinical use. Projects slow down or are redirected to other goals.
Key Conclusions
- The announcement of the development of two world-first gene therapy drugs against aging is a landmark event, indicating Russia’s intention to take a leading position in the rapidly developing field of longevity medicine.
- The scientific basis of the projects (RAGE blockade and exosome therapy) has experimental confirmation at the cellular level, lending a certain credibility to the claims.
- The implementation of the projects is backed by unprecedented state funding (a national project with a budget of >2 trillion rubles) and support at the highest political level.
- However, the path from cellular experiments to a registered drug for humans is extremely complex and takes years. A realistic forecast: first clinical applications are possible no earlier than 2030–2032 under optimistic circumstances.
- The ethical dilemma of accessibility remains open—the government must decide how to make high-tech and expensive therapy available to the general population.
The announcement in Saransk in April 2026 is not the finish line, but rather the ceremonial start of a marathon. Whether Russian scientists will be the first in the world to cross the finish line will be shown in the coming years—and the answer to this question will largely determine who wins the prize in the most ambitious race in modern medicine.
— Editorial Team
